BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 37572086)

  • 1. A phase 2 study of ibrutinib maintenance following first-line high-dose methotrexate-based chemotherapy for elderly patients with primary central nervous system lymphoma.
    Bairey O; Taliansky A; Glik A; Amiel A; Yust-Katz S; Gurion R; Zektser M; Porges T; Sarid N; Horowitz NA; Shina TT; Lebel E; Cohen A; Geiger KR; Raanani P; Wolach O; Siegal T
    Cancer; 2023 Dec; 129(24):3905-3914. PubMed ID: 37572086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A prospective phase II trial of response adapted whole brain radiotherapy after high dose methotrexate based chemotherapy in patients with newly diagnosed primary central nervous system lymphoma-analysis of acute toxicity profile and early clinical outcome.
    Adhikari N; Biswas A; Gogia A; Sahoo RK; Garg A; Nehra A; Sharma MC; Bhasker S; Singh M; Sreenivas V; Chawla R; Joshi G; Kumar L; Chander S
    J Neurooncol; 2018 Aug; 139(1):153-166. PubMed ID: 29633112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical outcomes of newly diagnosed primary CNS lymphoma treated with ibrutinib-based combination therapy: A real-world experience of off-label ibrutinib use.
    Chen F; Pang D; Guo H; Ou Q; Wu X; Jiang X; Wei X; Liu S; Huang L; Liang Z; Zhou D; Li W
    Cancer Med; 2020 Nov; 9(22):8676-8684. PubMed ID: 33068336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma--a randomized phase III trial (MATRix).
    Schorb E; Finke J; Ferreri AJ; Ihorst G; Mikesch K; Kasenda B; Fritsch K; Fricker H; Burger E; Grishina O; Valk E; Zucca E; Illerhaus G
    BMC Cancer; 2016 Apr; 16():282. PubMed ID: 27098429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II 'proof-of-concept' iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network.
    Soussain C; Choquet S; Blonski M; Leclercq D; Houillier C; Rezai K; Bijou F; Houot R; Boyle E; Gressin R; Nicolas-Virelizier E; Barrie M; Moluçon-Chabrot C; Lelez ML; Clavert A; Coisy S; Leruez S; Touitou V; Cassoux N; Daniau M; Ertault de la Bretonnière M; El Yamani A; Ghesquières H; Hoang-Xuan K
    Eur J Cancer; 2019 Aug; 117():121-130. PubMed ID: 31279304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Age-adjusted high-dose chemotherapy and autologous stem cell transplant in elderly and fit primary CNS lymphoma patients.
    Schorb E; Finke J; Ihorst G; Kasenda B; Fricker H; Illerhaus G
    BMC Cancer; 2019 Mar; 19(1):287. PubMed ID: 30925912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of upfront lenalidomide maintenance for primary central nervous system lymphoma following first-line methotrexate treatment: A retrospective study.
    Zhang Y; Wang W; Zhao D; Chong W; Chen C; Zhang W; Zhou D
    Cancer Med; 2024 May; 13(9):e7193. PubMed ID: 38738459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characteristics and Outcomes of Primary Central Nervous System Lymphoma: A Retrospective Study of 91 Cases in a Chinese Population.
    Mao C; Chen F; Li Y; Jiang X; Liu S; Guo H; Huang L; Wei X; Liang Z; Li W; Tang K
    World Neurosurg; 2019 Mar; 123():e15-e24. PubMed ID: 30326304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ibrutinib improves survival compared with chemotherapy in mantle cell lymphoma with central nervous system relapse.
    Rusconi C; Cheah CY; Eyre TA; Tucker D; Klener P; Giné E; Crucitti L; Muzi C; Iadecola S; Infante G; Bernard S; Auer RL; Pagani C; Duglosz-Danecka M; Mocikova H; van Meerten T; Cencini E; Marin-Niebla A; Williams ME; Angelillo P; Nicoli P; Arcari A; Morello L; Mannina D; Vitagliano O; Sartori R; Chiappella A; Sciarra R; Stefani PM; Dreyling M; Seymour JF; Visco C
    Blood; 2022 Oct; 140(17):1907-1916. PubMed ID: 35789260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab, methotrexate, procarbazine, vincristine and intensified cytarabine consolidation for primary central nervous system lymphoma (PCNSL) in the elderly: a LOC network study.
    Houillier C; Ghesquières H; Chabrot C; Soussain C; Ahle G; Choquet S; Nicolas-Virelizier E; Bay JO; Vargaftig J; Gaultier C; Touitou V; Martin-Duverneuil N; Cassoux N; Le Garff-Tavernier M; Costopoulos M; Faurie P; Hoang-Xuan K
    J Neurooncol; 2017 Jun; 133(2):315-320. PubMed ID: 28432587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of chemotherapy additional to high-dose methotrexate for primary central nervous system lymphoma (PCNSL).
    Bergner N; Monsef I; Illerhaus G; Engert A; Skoetz N
    Cochrane Database Syst Rev; 2012 Nov; 11():CD009355. PubMed ID: 23152274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
    Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
    Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of Key Factors Associated with Response to Salvage High-Dose Methotrexate Rechallenge in Primary Central Nervous System Lymphoma with First Relapse.
    Du P; Chen H; Shen L; Liu X; Wu X; Chen L; Cao A; Geng D
    Curr Oncol; 2022 Sep; 29(9):6642-6656. PubMed ID: 36135091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A retrospective study of 222 patients with newly diagnosed primary central nervous system lymphoma-Outcomes indicative for improved survival overtime.
    Bairey O; Lebel E; Buxbaum C; Porges T; Taliansky A; Gurion R; Goldschmidt N; Shina TT; Zektser M; Hofstetter L; Siegal T
    Hematol Oncol; 2023 Dec; 41(5):838-847. PubMed ID: 37403752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of new-onset primary central nervous system lymphoma in elderly patients using RMPV chemotherapy: a single-institution experience.
    Yoshida M; Kato T; Hiu T; Imaizumi Y; Morimoto S; Niino D; Yamaguchi S; Baba S; Ujifuku K; Yoshida K; Matsuo A; Morofuji Y; Izumo T; Okano S; Miyazaki Y; Matsuo T
    Int J Hematol; 2023 Sep; 118(3):333-339. PubMed ID: 37393325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current status and future of relapsed primary central nervous system lymphoma (PCNSL).
    Tyson RM; Siegal T; Doolittle ND; Lacy C; Kraemer DF; Neutwelt EA
    Leuk Lymphoma; 2003 Apr; 44(4):627-33. PubMed ID: 12769339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A nonradiation-containing, intermediate-dose methotrexate regimen for elderly patients with primary central nervous system lymphoma.
    Taoka K; Okoshi Y; Sakamoto N; Takano S; Matsumura A; Hasegawa Y; Chiba S
    Int J Hematol; 2010 Nov; 92(4):617-23. PubMed ID: 20967518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Retrospective Analysis of R-MPV Plus Response-adapted Whole-brain Radiotherapy for Elderly Patients with Primary Central Nervous System Lymphoma.
    Suzuki Y; Imoto N; Ishihara S; Fujiwara S; Ito R; Sakai T; Yamamoto S; Sugiura I; Kurahashi S
    Intern Med; 2022 May; 61(9):1345-1352. PubMed ID: 34670884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Evaluation of the Short-Term Efficacy and Safety of Orelabrutinib Combined with High-Dose Methotrexate in the First-line Treatment of Elderly Patients with High Risk Primary Central Nervous System Lymphoma].
    Xie Y; Qu S; Liao LS; Zheng ZH; Lin Y; Chen WM; Chen BY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Dec; 31(6):1714-1719. PubMed ID: 38071050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A single-center retrospective analysis of outcome measures and consolidation strategies for relapsed and refractory primary CNS lymphoma.
    Bonm AV; Gibson AW; Holmberg LA; Mielcarek M; McGranahan T; Taylor LP; Graber JJ
    J Neurooncol; 2021 Jan; 151(2):193-200. PubMed ID: 33398532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.